Please login to the form below

Not currently logged in
Email:
Password:

Reig Jofre and LeanBio launch Syna Therapeutics

The new company will focus on the development of biosimilars

Reig JofrePharmaceutical group Reig Jofre has entered into a strategic alliance with LeanBio, a four-year-old biotech company, to launch a new company focused on the development of biosimilars and ‘innovative’ molecules.

Much like its parent companies, Syna Therapeutics will be headquartered in Barcelona, Spain, where LeanBio’s founder Dr Andreu Soldevila will take the helm of the new business while Gabriel Roig becomes president of the board of directors.

Hoping to tap into a global biosimilar market of around €1,000m, Syna Therapeutics’ expertise will comprise of LeanBio’s biological development experience and Reig Jofre’s capability in formulation, stabilisation and pharmaceutical development of biological and injectable products.

Dr Soldevila said: “The development of a biosimilar is highly complex and one of the most important technological challenges of recent years.

“Bringing patients closer to biological treatments in a more sustainable way for national health systems means in addition a great social impact in a huge market.”

Syna Therapeutics will have to finance €9m to carry out the early stages of development, with the founding partners both contributing the initial capital estimated at €2m.

The new company has said it will also consider the entry of new financial or industrial commercial partners to support clinical development in its final stages.

Article by
Gemma Jones

26th March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....